United States · Platforms & data · MarketBeat
CG Oncology (NASDAQ:CGON) Earns Buy Rating from Truist Financial

Detailed summary
Truist Financial restated a "buy" rating and issued a $100.00 price objective (up from $85.00) on shares of CG Oncology in a research note on Tuesday.
MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.marketbeat.com)



